U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H22N2O
Molecular Weight 270.37
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOXYLAMINE

SMILES

CC(c1ccccc1)(c2ccccn2)OCCN(C)C

InChI

InChIKey=HCFDWZZGGLSKEP-UHFFFAOYSA-N
InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C17H22N2O
Molecular Weight 270.37
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/cdi/doxylamine.html

Doxylamine is an antihistamine commonly used as a sleep aid. This drug is also used to relieve symptoms of hay fever (allergic rhinitis), hives (rash or itching), and other allergic reactions. Doxylamine is a member of the ethanolamine class of antihistamines and has anti-allergy power far superior to virtually every other antihistamine on the market, with the exception of diphenhydramine (Benadryl). It is also the most powerful over-the-counter sedative available in the United States, and more sedating than many prescription hypnotics. In a study, it was found to be superior to even the barbiturate, phenobarbital for use as a sedative. Doxylamine is also a potent anticholinergic. Like other antihistamines, doxylamine acts by competitively inhibiting histamine at H1 receptors. It also has substantial sedative and anticholinergic effects. Used alone as a short-term sleep aid, in combination with other drugs as a night-time cold and allergy relief drug. Also used in combination with Vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women.

CNS Activity

Curator's Comment:: Penetrating into the central nervous system, the drug has a marked sedative effect, promoting sleep.

Originator

Curator's Comment:: Bendectin (DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE) was introduced in 1957 by Merrell Dow Pharmaceuticals

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
42.0 nM [Ki]
200.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unisom

Approved Use

Allergic rhinitis or other respiratory allergies (oral liquid only): Temporary relief of rhinorrhea, sneezing, itchy nose or throat, and itchy, watery eyes due to hay fever or other respiratory allergies Insomnia (tablets only): Reduce difficulty falling asleep

Launch Date

2.56089604E11
Primary
Unisom

Approved Use

Allergic rhinitis or other respiratory allergies (oral liquid only): Temporary relief of rhinorrhea, sneezing, itchy nose or throat, and itchy, watery eyes due to hay fever or other respiratory allergies Insomnia (tablets only): Reduce difficulty falling asleep

Launch Date

2.56089604E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
18.9 ng/mL
6.3 mg single, nasal
dose: 6.3 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
27.1 ng/mL
12.7 mg single, nasal
dose: 12.7 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
142 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.9 ng/mL
3.2 mg single, nasal
dose: 3.2 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
124.91 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
61.94 ng/mL
12.5 mg single, oral
dose: 12.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
99 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
83.3 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: PYRIDOXINE HYDROCHLORIDE
DOXYLAMINE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
168.6 ng/mL
40 mg 1 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: PYRIDOXINE HYDROCHLORIDE
DOXYLAMINE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
117.7 ng × h/mL
6.3 mg single, nasal
dose: 6.3 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
161.8 ng × h/mL
12.7 mg single, nasal
dose: 12.7 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
751.8 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
81.1 ng × h/mL
3.2 mg single, nasal
dose: 3.2 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1697.58 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
859.74 ng × h/mL
12.5 mg single, oral
dose: 12.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1280.9 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: PYRIDOXINE HYDROCHLORIDE
DOXYLAMINE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
3721.5 ng × h/mL
40 mg 1 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: PYRIDOXINE HYDROCHLORIDE
DOXYLAMINE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.8 h
6.3 mg single, nasal
dose: 6.3 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.1 h
12.7 mg single, nasal
dose: 12.7 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.4 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.2 h
3.2 mg single, nasal
dose: 3.2 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.45 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.23 h
12.5 mg single, oral
dose: 12.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.1 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10.1 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: PYRIDOXINE HYDROCHLORIDE
DOXYLAMINE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
11.9 h
40 mg 1 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: PYRIDOXINE HYDROCHLORIDE
DOXYLAMINE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
150 mg single, oral
Overdose
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources: Page: p.179
unknown, 2
n = 1
Health Status: unknown
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.179
Other AEs: Agitation, Dilated pupils...
Other AEs:
Agitation
Dilated pupils
Sources: Page: p.179
25 mg single, oral
Studied dose
Dose: 25 mg
Route: oral
Route: single
Dose: 25 mg
Sources: Page: p.133
healthy, 28 - 58
n = 12
Health Status: healthy
Age Group: 28 - 58
Sex: M+F
Population Size: 12
Sources: Page: p.133
Other AEs: Somnolence...
Other AEs:
Somnolence (50%)
Sources: Page: p.133
12.7 mg single, intranasal
Highest studied dose
Dose: 12.7 mg
Route: intranasal
Route: single
Dose: 12.7 mg
Sources: Page: p.133
unhealthy, 35.9 (8.00)
n = 24
Health Status: unhealthy
Condition: Chronic intermittent sleep impairment
Age Group: 35.9 (8.00)
Sex: M+F
Population Size: 24
Sources: Page: p.133
13 mg/kg single, oral
Overdose
Dose: 13 mg/kg
Route: oral
Route: single
Dose: 13 mg/kg
Sources: Page: p.1
unknown
Health Status: unknown
Sources: Page: p.1
Other AEs: Rhabdomyolysis...
Other AEs:
Rhabdomyolysis
Sources: Page: p.1
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Co-administed with::
pyridoxine hydrochloride(20 mg oral; 1-2/day)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Nausea and vomiting of pregnancy
Sources: Page: p.1
Other AEs: Somnolence...
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Co-administed with::
pyridoxine hydrochloride(20 mg oral; 1-2/day)
CNS depressants
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Nausea and vomiting of pregnancy
Sources: Page: p.3
Other AEs: Drowsiness...
Other AEs:
Drowsiness (grade 3)
Sources: Page: p.3
20 mg single, oral
Recommended
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
pyridoxine hydrochloride(20 mg oral single dose)
Sources: Page: p.48
healthy
n = 48
Health Status: healthy
Sex: F
Population Size: 48
Sources: Page: p.48
Disc. AE: Vomiting...
AEs leading to
discontinuation/dose reduction:
Vomiting
Sources: Page: p.48
20 mg 2 times / day steady, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: steady
Dose: 20 mg, 2 times / day
Co-administed with::
pyridoxine hydrochloride(20 mg oral single dose)
Sources: Page: p.63
healthy
n = 37
Health Status: healthy
Sex: F
Population Size: 37
Sources: Page: p.63
Disc. AE: Vomiting, Decreased hemoglobin...
AEs leading to
discontinuation/dose reduction:
Vomiting
Decreased hemoglobin
Visual impairment
Sources: Page: p.63
AEs

AEs

AESignificanceDosePopulation
Agitation
150 mg single, oral
Overdose
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources: Page: p.179
unknown, 2
n = 1
Health Status: unknown
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.179
Dilated pupils
150 mg single, oral
Overdose
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources: Page: p.179
unknown, 2
n = 1
Health Status: unknown
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.179
Somnolence 50%
25 mg single, oral
Studied dose
Dose: 25 mg
Route: oral
Route: single
Dose: 25 mg
Sources: Page: p.133
healthy, 28 - 58
n = 12
Health Status: healthy
Age Group: 28 - 58
Sex: M+F
Population Size: 12
Sources: Page: p.133
Rhabdomyolysis
13 mg/kg single, oral
Overdose
Dose: 13 mg/kg
Route: oral
Route: single
Dose: 13 mg/kg
Sources: Page: p.1
unknown
Health Status: unknown
Sources: Page: p.1
Somnolence
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Co-administed with::
pyridoxine hydrochloride(20 mg oral; 1-2/day)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Nausea and vomiting of pregnancy
Sources: Page: p.1
Drowsiness grade 3
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Co-administed with::
pyridoxine hydrochloride(20 mg oral; 1-2/day)
CNS depressants
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Nausea and vomiting of pregnancy
Sources: Page: p.3
Vomiting Disc. AE
20 mg single, oral
Recommended
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
pyridoxine hydrochloride(20 mg oral single dose)
Sources: Page: p.48
healthy
n = 48
Health Status: healthy
Sex: F
Population Size: 48
Sources: Page: p.48
Decreased hemoglobin Disc. AE
20 mg 2 times / day steady, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: steady
Dose: 20 mg, 2 times / day
Co-administed with::
pyridoxine hydrochloride(20 mg oral single dose)
Sources: Page: p.63
healthy
n = 37
Health Status: healthy
Sex: F
Population Size: 37
Sources: Page: p.63
Visual impairment Disc. AE
20 mg 2 times / day steady, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: steady
Dose: 20 mg, 2 times / day
Co-administed with::
pyridoxine hydrochloride(20 mg oral single dose)
Sources: Page: p.63
healthy
n = 37
Health Status: healthy
Sex: F
Population Size: 37
Sources: Page: p.63
Vomiting Disc. AE
20 mg 2 times / day steady, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: steady
Dose: 20 mg, 2 times / day
Co-administed with::
pyridoxine hydrochloride(20 mg oral single dose)
Sources: Page: p.63
healthy
n = 37
Health Status: healthy
Sex: F
Population Size: 37
Sources: Page: p.63
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​
PubMed

PubMed

TitleDatePubMed
[Hyperemesis gravidarum--etiology and treatment].
2003 Sep-Oct
Neuropharmacological profile of hydroalcohol extract of Valeriana edulis ssp. procera roots in mice.
2004 Apr
Pre-emptive therapy for severe nausea and vomiting of pregnancy and hyperemesis gravidarum.
2004 Aug
Is lack of morning sickness teratogenic? A prospective controlled study.
2004 Aug
Differential protonation and dynamic structure of doxylamine succinate in solution using 1H and 13C NMR.
2004 Jul
Determinants of women's decision making on whether to treat nausea and vomiting of pregnancy pharmacologically.
2004 Jul-Aug
Treatment of primary insomnia.
2004 May-Jun
Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding.
2004 Oct
Effect of (+) or (-) camphorsulfonic acid additives to the mobile phase on enantioseparations of some basic drugs on a Chiralcel OD column.
2005 Aug 12
Separation of enantiomers in capillary electrophoresis with contactless conductivity detection.
2005 Aug 5
Prophylactic Diclectin reduces the incidence of postoperative vomiting.
2005 Jan
[Efficacy of donormil in the treatment of insomnia in patients with vascular encephalopathy].
2006
Optimization by factorial design of a capillary zone electrophoresis method for the simultaneous separation of antihistamines.
2006 May 1
[Juvenile pityriasis rubra pilaris].
2006 Oct
[Unilateral laterothoracic exanthema].
2006 Oct
The risk of risk reduction: can postmarket surveillance pose more risk than benefit?
2007
Efficacy of a single evening dose of syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms.
2007 Apr
Comparison of lactated Ringer's solution and 0.9% saline in the treatment of rhabdomyolysis induced by doxylamine intoxication.
2007 Apr
Risk factors for rhabdomyolysis following doxylamine overdose.
2007 Aug
Inactivation of anthracyclines by serum heme proteins.
2007 Jun
Separation of cold medicine ingredients using a precise MEKC method at elevated pH.
2007 Jun
[Chemicotoxicological evaluation of doxylamine].
2007 May-Jun
An estimate of the proportion of drug-facilitation of sexual assault in four U.S. localities.
2007 Nov
Differentially expressed genes in embryonic cardiac tissues of mice lacking Folr1 gene activity.
2007 Nov 20
Managing nausea and vomiting of pregnancy: a survey of obstetrician-gynecologists.
2007 Oct
A thyrotoxicosis outbreak due to dietary pills in Paris.
2008 Dec
Representation and re-presentation in litigation science.
2008 Jan
Sleep complaints: Whenever possible, avoid the use of sleeping pills.
2008 Oct
Doxylamine toxicity: seizure, rhabdomyolysis and false positive urine drug screen for methadone.
2009
Extended suicide using an atypical stud gun.
2009 Aug 10
Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrocholoride (Diclectin) and oral solutions of these drugs in healthy women of childbearing age.
2009 Fall
Long-term neurodevelopment of children exposed to maternal nausea and vomiting of pregnancy and diclectin.
2009 Jul
Comparison of chiral separation of basic drugs in capillary electrophoresis and liquid chromatography using neutral and negatively charged cyclodextrins.
2009 Jul 10
The identification of ingested dandelion juice in gastric contents of a deceased person by direct sequencing and GC-MS methods.
2009 May
Does advice from pharmacy staff vary according to the nonprescription medicine requested?
2009 Nov
Acute renal failure caused by pheniramine maleate induced rhabdomyolysis: an unusual case.
2009 Oct
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009 Oct 2
Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin.
2010 Apr
Learning curves for pediatric laparoscopy: how many operations are enough? The Amsterdam experience with laparoscopic pyloromyotomy.
2010 Aug
Optimal management of nausea and vomiting of pregnancy.
2010 Aug 4
Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial.
2010 Dec
Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands.
2010 Dec 5
Authenticity of claims made in drug promotional literature.
2010 Feb
Managing hyperemesis gravidarum: a multimodal challenge.
2010 Jul 15
[Hyperemesis gravidarum: a rare but potentially severe complication of the first trimester of pregnancy].
2010 Jun 20
A tendency for re-offending in drug-facilitated crime.
2010 Mar 20
Biotransformation of ginsenosides Rb1, Rg3 and Rh2 in rat gastrointestinal tracts.
2010 May 26
An unusual death involving a sensory deprivation tank.
2010 Nov
An overdose death involving the insufflation of extended-release oxymorphone tablets.
2010 Oct
Clinical practice. Nausea and vomiting in pregnancy.
2010 Oct 14
Patents

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Allergic Rhinitis Doxylamine 5 mg oral tablet, chewable: 10 mg orally every 4 to 6 hours not to exceed 6 doses daily. Usual Adult Dose for Allergic Conjunctivitis Doxylamine 5 mg oral tablet, chewable: 10 mg orally every 4 to 6 hours not to exceed 6 doses daily. Usual Adult Dose for Insomnia 12 years of age and older: 25 mg orally 30 minutes before bed
Route of Administration: Oral
In Vitro Use Guide
Doxylamine at 50 ug/ml inhibited both differentiation and proliferation in rat embryo limb bud cell cultures
Substance Class Chemical
Created
by admin
on Sat Jun 26 12:10:40 UTC 2021
Edited
by admin
on Sat Jun 26 12:10:40 UTC 2021
Record UNII
95QB77JKPL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DOXYLAMINE
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
DOXYLAMINE [VANDF]
Common Name English
PYRIDINE, 2-(.ALPHA.-(2-(DIMETHYLAMINO)ETHOXY)-.ALPHA.-METHYLBENZYL)-
Systematic Name English
2-(.ALPHA.(2-(DIMETHYLAMINO)ETHOXY)-.ALPHA.-METHYLBENZYL)PYRIDINE
Systematic Name English
(+/-)-DOXYLAMINE
Common Name English
DOXYLAMINE [INN]
Common Name English
ETHANAMINE, N,N-DIMETHYL-2-(1-PHENYL-1-(2-PYRIDINYL)ETHOXY)-
Systematic Name English
DOXYLAMINE [MI]
Common Name English
DOXYLAMINE [HSDB]
Common Name English
DOXYLAMINE [WHO-DD]
Common Name English
N,N-DIMETHYL-2-(1-PHENYL-1-(2-PYRIDINYL)ETHOXY)ETHANAMINE
Systematic Name English
Classification Tree Code System Code
WHO-ATC R06AA59
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
CFR 21 CFR 520.784
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
WHO-VATC QR06AA59
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
WHO-ATC R06AA09
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
LIVERTOX 330
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
NCI_THESAURUS C29578
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
NDF-RT N0000175750
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
WHO-VATC QR06AA09
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
Code System Code Type Description
EVMPD
SUB06394MIG
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY
DRUG BANK
DB00366
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY
FDA UNII
95QB77JKPL
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY
IUPHAR
7171
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY
DRUG CENTRAL
962
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY
NCI_THESAURUS
C61738
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY
CAS
469-21-6
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY
ECHA (EC/EINECS)
207-414-2
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY
CAS
102737-83-7
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
SUPERSEDED
PUBCHEM
3162
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY
MESH
D004319
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY
MERCK INDEX
M4759
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY Merck Index
EPA CompTox
469-21-6
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY
WIKIPEDIA
DOXYLAMINE
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY
INN
1782
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY
HSDB
5184
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY
RXCUI
3642
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY RxNorm
LACTMED
Doxylamine
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY
ChEMBL
CHEMBL1004
Created by admin on Sat Jun 26 12:10:40 UTC 2021 , Edited by admin on Sat Jun 26 12:10:40 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
ACTIVE ENANTIOMER->RACEMATE
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
Could be free or glucuronide conjugate
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
METABOLITE -> PARENT
Could be free or glucuronide conjugate
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC